Phenylalanine

Phenylalanine

SCHEMBL1253619

CC(C)C[C@H](N)[C@@H](O)CC(=O)O.N[C@@H](Cc1ccccc1)C(=O)O

nearest known ligand 0.59

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC7A5 Q01650 2/20 0.59
ALPI P09923 1/20 0.59
PKM P14618 1/20 0.59
PTGS1 P23219 1/20 0.59
XIAP P98170 1/20 0.59
ANPEP P15144 3/20 0.54
RNPEP Q9H4A4 3/20 0.54
DNPEP Q9ULA0 3/20 0.54
LTA4H P09960 3/20 0.51
SLC1A3 P43003 1/20 0.49
SLC1A2 P43004 1/20 0.49
SLC1A1 P43005 1/20 0.49
SLC15A1 P46059 1/20 0.46
CPA1 P15085 2/20 0.45
CPB1 P15086 1/20 0.45
CPA3 P15088 1/20 0.45
CPB2 Q96IY4 1/20 0.45
LAP3 P28838 2/20 0.43
NOS3 P29474 1/20 0.43
NOS1 P29475 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Dl-Phenylalanine SCHEMBL1253618 1.00 SLC7A5 (0.59) SLC7A5ALPIPKMPTGS1XIAP
Phenylalanine SCHEMBL7273524 0.86 ALPI (0.44) SLC7A5ALPIPKMPTGS1XIAP
Dl-Phenylalanine SCHEMBL27260374 0.86 ALPI (0.44) SLC7A5ALPIPKMPTGS1XIAP
Dl-Phenylalanine SCHEMBL31087886 0.82 SLC7A5 (0.76) SLC7A5ALPIPKMPTGS1XIAP
Dl-Phenylalanine SCHEMBL208388 0.82 SLC7A5 (0.76) SLC7A5ALPIPKMPTGS1XIAP
Phenylalanine SCHEMBL10945389 0.82 SLC7A5 (0.76) SLC7A5ALPIPKMPTGS1XIAP
Phenylalanine SCHEMBL2634732 0.82 SLC7A5 (0.76) SLC7A5ALPIPKMPTGS1XIAP
D-Phenylalanine SCHEMBL10775923 0.82 SLC7A5 (0.76) SLC7A5ALPIPKMPTGS1XIAP
Phenylalanine SCHEMBL208389 0.82 SLC7A5 (0.76) SLC7A5ALPIPKMPTGS1XIAP
Dl-Phenylalanine SCHEMBL27551454 0.82 SLC7A5 (0.76) SLC7A5ALPIPKMPTGS1XIAP

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1409654-B1 IMMUNOLOGICAL CONTROL OF BETA-AMYLOID LEVELS IN VIVO BOSTON BIOMEDICAL RES INST (US) 2008-08-20 EP claimed
US-7413884-B2 Immunological control of β-amyloid levels in vivo BOSTON BIOMEDICAL RESEARCH INSTITUTE (US) 2008-08-19 US claimed
EP-3070100-B1 HUMANIZED ANTIBODIES THAT SEQUESTER AMYLOID BETA PEPTIDE WASHINGTON UNIV ST LOUIS (US) 2021-07-07 EP disclosed
EP-3150633-A1 HUMANIZED ANTIBODIES THAT SEQUESTER AMYLOID BETA PEPTIDE WASHINGTON UNIVERSITY ST. LOUIS (US) 2017-04-05 EP disclosed
EP-1481992-B1 Humanized antibodies that sequester amyloid beta peptide UNIV ST LOUIS (US) 2016-11-02 EP disclosed
EP-3070100-A1 HUMANIZED ANTIBODIES THAT SEQUESTER AMYLOID BETA PEPTIDE WASHINGTON UNIVERSITY ST. LOUIS (US) 2016-09-21 EP disclosed
US-20160039915-A1 IMMUNOLOGICAL CONTROL OF BETA-AMYLOID LEVELS IN VIVO BOSTON BIOMEDICAL RESEARCH INSTITUTE (US) 2016-02-11 US disclosed
CN-104341500-A HUMANIZED ANTIBODIES THAT SEQUESTER A beta PEPTIDE UNIV WASHINGTON 2015-02-11 CN disclosed
CN-101670105-B Humanized antibodies chelated with amylord beta peptide UNIV WASHINGTON 2014-08-06 CN disclosed
US-20140086937-A1 IMMUNOLOGICAL CONTROL OF BETA-AMYLOID LEVELS IN VIVO BOSTON BIOMEDICAL RESEARCH INSTITUTE (US) 2014-03-27 US disclosed
US-8591894-B2 Humanized antibodies that sequester amyloid beta peptide ELI LILLY AND COMPANY (US) 2013-11-26 US disclosed
US-20030235897-A1 Immunological control of beta-amyloid levels in vivo BOSTON BIOMEDICAL RESEARCH INSTITUTE (US) 2003-12-25 US disclosed
CN-1426423-A Humanized antibodies that sequester amyloid beta peptide UNIV WASHINGTON (US) 2003-06-25 CN disclosed
US-6582945-B1 Vectorized antibody for use in the treatment of alzheimer's disease BOSTON BIOMEDICAL RESEARCH INSTITUTE 2003-06-24 US disclosed
WO-2003016466-A2 ANTI-Aβ ANTIBODIES ELI LILLY AND COMPANY (US) 2003-02-27 WO disclosed
EP-1257584-A2 HUMANIZED ANTIBODIES THAT SEQUESTER AMYLOID BETA PEPTIDE WASHINGTON UNIVERSITY ST. LOUIS (US) 2002-11-20 EP disclosed
US-20020136718-A1 Immunological control of beta-amyloid levels in vivo BOSTON BIOMEDICAL RESEARCH INSTITUTE (US) 2002-09-26 US disclosed
US-20020102261-A1 Immunological control of beta-amyloid levels in vivo BOSTON BIOMEDICAL RESEARCH INSTITUTE (US) 2002-08-01 US disclosed
WO-2001062801-A2 HUMANIZED ANTIBODIES THAT SEQUESTER AMYLOID BETA PEPTIDE WASHINGTON UNIVERSITY (US) 2001-08-30 WO disclosed
US-6140091-A GENERATING CATALYTIC ANTIBODIES; IMMUNIZE ANIMAL, SCREEN FOR MONOCLONAL ANTIBODIES, IMMUNIZE ANIMAL WITH ANTIBODY, RECOVER IDIOTYPIC MONOCLONAL ANTIBODIES, IMMUNIZE ANIMAL WITH IDIOTYPIC ANTIBODY AND RECOVER PRODUCT BOSTON BIOMEDICAL RESEARCH INSTITUTE (US) 2000-10-31 US disclosed